# A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.

> **NCT03103724** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 68 (actual)

## Conditions studied

- Carcinoma Prostate

## Interventions

- **DRUG:** Xtandi

## Key facts

- **NCT ID:** NCT03103724
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03103724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03103724, "A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03103724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*